This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "EMBER Study - Imlunestrant, an Oral SERD, in Combination With HER2 Directed Therapy +/- Abemaciclib in ER+/HER2+ Advanced BC"

87 views
July 2, 2024
Comments 0
Login to view comments. Click here to Login